dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gaspar, N. |
dc.contributor.author | Campbell Hewson, Quentin |
dc.contributor.author | Gallego Melcón, Soledad |
dc.contributor.author | Locatelli, F. |
dc.contributor.author | Venkatramani, R. |
dc.contributor.author | Hecker-Nolting, S. |
dc.date.accessioned | 2022-04-25T13:16:10Z |
dc.date.available | 2022-04-25T13:16:10Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Gaspar N, Campbell-Hewson Q, Gallego Melcon S, Locatelli F, Venkatramani R, Hecker-Nolting S, et al. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). ESMO Open. 2021 Oct 1;6(5):100250. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7399 |
dc.description | Osteosarcoma; Pediàtrica; Tumors sòlids |
dc.description.sponsorship | This work was supported by Eisai Inc., Woodcliff Lake, NJ, USA and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Ossos - Malalties, en els infants |
dc.subject | Ossos - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Bone Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100250 |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | neoplasias óseas |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100250 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gaspar N] Department of Childhood and Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France. [Campbell-Hewson Q] The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK. [Gallego Melcon S] Servei d'Oncologia i Hematologia Pediàtrica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Locatelli F] Department of Pediatric Hematology and Oncology, Ospedale Pediatrico Bambino Gesù, University of Rome, Rome, Italy. [Venkatramani R] Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA. [Hecker-Nolting S] Department of Pediatric Oncology, Hematology, Immunology, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany |
dc.identifier.pmid | 34562750 |
dc.identifier.wos | 000704803800003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |